Trial Profile
Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study).
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Sep 2019
Price :
$35
*
At a glance
- Drugs Atenolol (Primary) ; Telmisartan (Primary)
- Indications Aortic valve disorders
- Focus Therapeutic Use
- Acronyms BAV
- 12 Aug 2019 Status changed from completed to discontinued.
- 15 Aug 2016 Status changed from recruiting to completed.
- 26 Nov 2012 Planned number of patients changed from 352 to 416 as reported by ClinicalTrials.gov.